Bio Impact Capital LLC Cullinan Oncology, Inc. Transaction History
Bio Impact Capital LLC
- $611 Million
- Q1 2024
A detailed history of Bio Impact Capital LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 7,648,268 shares of CGEM stock, worth $133 Million. This represents 21.33% of its overall portfolio holdings.
Number of Shares
7,648,268
Previous 7,648,268
-0.0%
Holding current value
$133 Million
Previous $77.9 Million
67.22%
% of portfolio
21.33%
Previous 18.94%
Shares
2 transactions
Others Institutions Holding CGEM
# of Institutions
118Shares Held
42.8MCall Options Held
12.6KPut Options Held
4.9K-
Chi Advisors LLC New York, NY3.41MShares$59.5 Million15.23% of portfolio
-
Bvf Inc San Francisco, CA3.2MShares$55.8 Million1.63% of portfolio
-
Blue Owl Capital Holdings LP New York, NY2.92MShares$51 Million13.21% of portfolio
-
Franklin Resources Inc San Mateo, CA2.7MShares$47 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.43MShares$42.4 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $795M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...